Ovid Therapeutics Inc.
NASDAQ:OVIDBiotechnology
-$0.11 today
- Market cap
- $426.53M
- Beta
- 0.18
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.33
Volume 2.16M
Average 3.07M
OVID Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Ovid Therapeutics Inc.NASDAQ: OVID
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $35K fell 75.2% year over year, behind the -73.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 105.9% from the prior quarter. Over 3 fiscal years it compounded at -39.9% a year.
Context
- Depreciation & amortization amounted to 4.1% of revenue in FY2025, down 104.2 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -75.2% toward the trailing-twelve-month pace of -73.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 300K USD
- Year-over-year change
- -51.1%
- 4-year CAGR
- +6.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 300K | -51.1% |
| FY2024 | 2024-12-31 | 613K | +7.9% |
| FY2023 | 2023-12-31 | 568K | -58.9% |
| FY2022 | 2022-12-31 | 1.38M | +482.8% |
| FY2021 | 2021-12-31 | 237.08K | — |
Depreciation & Amortization vs competitors
How OVID compares with its peers on the latest reported figures
- OVID's LTM Mar 2026 depreciation & amortization of $167K is the lowest of the 11 companies compared; the peer median is $3.8M.
- Its year-over-year change of -73.0% is the lowest of 11, against a peer median of +3.3%.
- Depreciation & amortization amounts to 2.3% of revenue for OVID, versus a peer median of 12.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $34.01M | -4.7% | +24.3% | 5.1% | |
| LTM Mar 2026 | $12.82M | +2.6% | +13.6% | 16.1% | |
| LTM Mar 2026 | $10.18M | +1.0% | +20.7% | — | |
| LTM Mar 2026 | $8.99M | +4.0% | -4.3% | 12.5% | |
| LTM Mar 2026 | $3.98M | -12.6% | -13.1% | 10.9% | |
| LTM Mar 2026 | $3.62M | +20.6% | -8.0% | 24.9% | |
| LTM Mar 2026 | $3.54M | +69.2% | +4.6% | 11.0% | |
| LTM Mar 2026 | $3.18M | +0.0% | -1.1% | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $2.12M | +4.8% | +22.0% | — |
| LTM Jun 2026 | $1.28M | +10.5% | -22.8% | 23.3% | |
| LTM Mar 2026 | $167K | -73.0% | -39.9% | 2.3% | |
| Peer median (excluding OVID) | $3.8M | +3.3% | +1.8% | 12.5% | |
Competitors are the stored peer set for OVID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 208.38M | 1.5M | 392K | 566K | 7.25M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 300K |
| Gross Profit | 208.38M | 1.5M | 392K | 566K | 6.95M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 95.9% |
| Research & Development | 46.94M | 24.62M | 28.59M | 36.77M | 25.58M |
| Selling, General & Admin | 37.23M | 32.43M | 29.59M | 25.68M | 24.11M |
| Operating Expenses | 84.17M | 57.05M | 59.67M | 62.45M | 49.39M |
| Depreciation & Amortization | 237.08K | 1.38M | 568K | 613K | 300K |
| EBITDA | 124.45M | (54.17M) | (57.01M) | (57.77M) | (17.11M) |
| EBITDA Margin | 59.7% | -3604.5% | -14544.1% | -10207.1% | -236.0% |
| Operating Income | 124.21M | (55.55M) | (59.28M) | (61.89M) | (42.44M) |
| Operating Margin | 59.6% | -3696.4% | -15122.7% | -10933.7% | -585.2% |
| Interest Income | 0 | 0 | 4.9M | 3.9M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (45.69K) | 1.38M | 6.94M | 35.45M | 25.03M |
| Income Before Tax | 124.16M | (54.17M) | (52.34M) | (26.43M) | (17.41M) |
| Pre-Tax Margin | 59.6% | -3604.7% | -13351.8% | -4670.1% | -240.1% |
| Income Tax Expense | 1.33M | 0 | 0 | 0 | 0 |
| Net Income | 122.83M | (54.17M) | (52.34M) | (26.43M) | (17.41M) |
| Net Margin | 58.9% | -3604.7% | -13351.8% | -4670.1% | -240.1% |
| EPS (Basic) | 1.78 | (0.77) | (0.74) | (0.37) | (0.24) |
| EPS (Diluted) | 1.76 | (0.77) | (0.74) | (0.37) | (0.24) |
| Weighted Avg Shares | 67.48M | 70.43M | 70.58M | 70.91M | 73.74M |
| Weighted Avg Shares (Diluted) | 68.07M | 70.43M | 70.58M | 70.91M | 73.74M |
Ovid Therapeutics Inc.
NASDAQ:OVID
Intrinsic Alpha fair value
Locked
Current Price
$2.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.